Development of a cAMP sensor with decreased pH sensitivity. by Katy L. Everett (461878)

Decreased oscillatory flow decreases <i>klf2a</i> expression. by Julien Vermot (257990)

“…(L) Quantitative RT-PCR showing the expression level of several flow-responsive genes after lidocaine treatment. <i>klf2a</i> expression is significantly decreased after 6 and 10 h of treatment and is restored by incubation at 34°C; 100% of expression corresponds to a normal expression level. …”

The decrease in c-Myc protein levels in A549 cells was primarily due to proteasomal degradation. by Qin Li (36669)

Compound 1 decreased the ΔΨm level of HepG-2 cells. by Jing Zhang (23775)

Decreased 5-hmC expression was associated with <i>TET2</i> downregulation. by Xuejiao Shi (1684186)

Decreased macrophage recruitment correlates with decreased angiogenesis. by Johanna R. Reed (306158)

“…<p>A) Quantification of BrdU incorporation demonstrates that decreased macrophage infiltration does not significantly correlate with a change in epithelial cell proliferation (N.S. = not significant). …”

NFκB-p50 knockdown decreases CD44 expression. by Shannon M. Smith (115335)

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

KDM6A mRNA expression is decreased in PTFE mice. by Simon Lebek (9756148)

KOR-agonist (U50'488) and MOR-agonist (DAMGO) decrease symptoms in OVA-allergic mice. by Swantje C. Duncker (154707)

SDG decreases p70S6K1 and increases AMPK protein expression in iron treated H9c2 cells. by Stephanie Puukila (568109)

BMT decreases HFD-induced weight gain associated with decreased preadipocyte number and insulin secretion by Saeed Katiraei (3956147)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)

EQI decreases malonyl-CoA levels in <i>S</i>. <i>aureus</i>. by Erica C. Larson (1344687)

Decreased fibrin deposition in hypoxic C3−/− mice. by Eileen M. Bauer (337320)

Purified apolipoproteins decrease endothelial exocytosis. by Scott J. Cameron (838315)

Stroma decreases spheroid size by decreasing cell width. by Karen F. Chambers (224337)

EC50 and percentage decrease in intracellular <i>Listeria</i> viability for effective compounds. by Marie-Eve Charbonneau (5658799)

Decreased expression levels of SPI-1 genes in <i>bipA</i>-deleted strain at 20°C. by Eunsil Choi (8271039)

Subjects: